| abstract |
The invention concerns the use of at least one living attenuated immunogenic Salmonella-vaccine strain, with an envelope marker making it sensitive to macrolide antibiotics, in the production of a living vaccine intended for a specific host. In the event of the vaccine causing an infection in another host, effective therapeutic treatment of the infected host is possible using macrolides |